$TEVA is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 7 active Congressional signals mentioning $TEVA, including 7 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
HR8083 is an early-stage bill (referred to four committees) that would incentivize OTC switches for routine oral contraceptives via priority review and fee waivers for drugmakers. No explicit funding is authorized — only a GAO study on federal contraceptive funding is directed. At this procedural stage, the bill has zero binding market impact. Pfizer ($PFE at $26.69, down -4.95% over 30 days) and Bristol-Myers Squibb ($BMY at $59.64, down -1.67% over 30 days) have no current revenue exposure to this pathway.
HR8143 mandates Medicare Part D formularies give preferred placement to generic drugs and biosimilars with lower wholesale acquisition costs than brand-name reference products, effective January 1, 2027. This directly benefits pure-play generics manufacturers $VTRS and $TEVA by guaranteeing formulary access and restricting PBM utilization management. The bill is early stage (referred to committee) but has bipartisan sponsorship and clear structural impact on the Part D market.
HR 7902 (Safeguarding Women from Chemical Abortion Act) would withdraw FDA approval for mifepristone for pregnancy termination and create a federal tort for harm from chemical abortion drugs. The bill was introduced March 12, 2026, referred to two committees, and is in early legislative stages with only 6 cosponsors. Revenue exposure for $PFE and $TEVA is immaterial to their overall financials — less than 0.1% of revenue for each. The bill has effectively no near-term market impact.
HR6485 (Skinny Labels, Big Savings Act) creates a statutory safe harbor protecting generic and biosimilar manufacturers from patent infringement liability when marketing drugs for non-patented indications, directly reversing the GlaxoSmithKline v. Teva precedent. Generic makers TEVA and VTRS are structural winners, with reduced litigation risk supporting their generic launch strategies. Brand-name manufacturers AMGN, PFE, JNJ, and MRK face accelerated competitive erosion on their top-selling drugs. The bill is early-stage (referred to House Judiciary), but companion Senate bill S43 signals bipartisan interest.
HR6052, the Elijah E. Cummings Family Asthma Act, is an early-stage bill that amends the Public Health Service Act to direct further asthma research. It authorizes no specific funding, mandates no changes to healthcare providers or pharmaceutical companies, and has been referred to committee with four cosponsors. No near-term market impact is expected.
The Biosimilar Red Tape Elimination Act (HR5526) would remove FDA interchangeability study requirements, speeding market entry for $VTRS and $TEVA biosimilars. Market data shows $VTRS +11.55% and $TEVA +17.73% over 30 days, consistent with investors pricing in this regulatory catalyst. Innovators $AMGN (-2.11% 30-day), $JNJ (-5.95%), and $BIIB (+4.18%) face structural margin pressure as pharmacy-level substitution becomes automatic upon biosimilar approval.
The Skinny Labels, Big Savings Act (S.43) creates a statutory safe harbor protecting generic drug manufacturers from patent infringement lawsuits when they seek FDA approval for and market 'skinny label' generics. The bill is in early legislative stages (referred to Senate Judiciary Committee, January 2025). If enacted, it structurally favors generic manufacturers like Teva ($TEVA) and Viatris ($VTRS) by eliminating litigation risk, while negatively impacting brand-name drug companies whose multi-use patents will no longer block generic entry. Teva's stock has rallied 13.36% in 7 days and 24.8% in 30 days; Viatris gained 1.49% (7-day) and 15.51% (30-day), reflecting early market pricing of this regulatory catalyst.